Long-term Anticoagulation for Venous Thromboembolism: Duration of Treatment and Management of Warfarin Therapy - 05/08/11
Henderson Division, Hamilton Health Sciences, Henderson General Hospital, 711 Concession Street, Hamilton, ON L8V 1C3, Canada.Résumé |
Treatment of venous thromboembolism (VTE) should be continued until the reduction of recurrent VTE that anticoagulation is expected to achieve no longer outweighs the increase in bleeding associated with therapy, or until the patient wants to stop treatment even if treatment is expected to be of benefit. Reversibility of risk factors for VTE is the most important factor that influences risk of recurrence and duration of therapy. VTE associated with a reversible risk factor (eg, surgery) is treated for 3 months; unprovoked VTE often benefits from indefinite therapy provided patients do not have risk factors for bleeding; and cancer-associated VTE is usually treated indefinitely. A systematic approach to managing warfarin therapy improves its efficacy, safety, and acceptability.
Le texte complet de cet article est disponible en PDF.Keywords : Venous thromboembolism, Deep vein thrombosis, Pulmonary embolism, Treatment, Warfarin, Duration of therapy
Plan
| Dr Kearon is a Career Investigator of the Heart and Stroke Foundation of Ontario and is supported by a Canadian Institutes of Health Research Team Grant in Venous Thromboembolism (FRN 79846). |
|
| Conflict of Interest: Dr Kearon is an advisor to Boehringer Ingelheim. |
Vol 31 - N° 4
P. 719-730 - décembre 2010 Retour au numéro
Article précédent
- New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors
- Timothy A. Morris
- Venous Thromboembolism in Pregnancy
- Paul E. Marik
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?